department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ohtuvayre · pharmadog

pharmadog
drugs
Ohtuvayre

drug · small molecule

patient view →

ensifentrine

Marketedupdated 2mo ago

by Verona Pharma Ltd🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 investigational indications.

targets

Phosphodiesterase 3Phosphodiesterase 4

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Ohtuvayre

trade names

Ohtuvayre

generic

ensifentrine

MOA

Phosphodiesterase 3 inhibitor; Phosphodiesterase 4 inhibitor

indication

Bronchiectasis

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 26, 2029

~3.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

Jun 25, 2044formulationUS 12251384
Feb 20, 2043formulationUS 12409180
Sep 15, 2035formulationUS 10945950
Sep 15, 2035formulationUS 9956171
Aug 21, 2031compositionUS 9062047

FDA exclusivities (1)

Jun 26, 2029NCENew Chemical Entity (5y)3.0y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying ensifentrine

phase2A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPDrecruitingn=480
phase2Effect of Ensifentrine on Sputum Markers of Inflammation in COPDrecruitingn=56
phase2A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Diseasecompletedn=33
phase2A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasisrecruitingn=180
phase3A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Diseasecompletedn=526
phase3Effect of Ensifentrine Treatment on CAT Scorecompletedn=20
phase3A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDcompletedn=763
phase3A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPDcompletedn=790

more trials →